Laboratory study of NY-198 and clinical evaluation in respiratory tract infections

Seiichi Aonuma, Yutaka Tokue, Naoto Kitamura, Yoshihiro Honda, Reiko Ono, Akira Watanabe, Kohtaro Ohizumi, Kiyoshi Konno, Kohsaku Nagai

    研究成果: Article査読

    1 被引用数 (Scopus)

    抄録

    We examined the in vitro antimicrobial activity of NY-198, a newly developed quinolone derivative by the broth-dilution method using an MIC-2000 system, and compared minimum inhibitory concentrations (MICs) of NY-198 against 170 clinical isolates with those of norfloxacin (NFLX), ofloxacin (OFLX) and ciprofloxacin (CPFX). Against S. aureus, NY-198 was less active than CPFX and OFLX but more active than NFLX. However, against all other isolates tested (E. colt, K. pneumoniae, S. marcescens, E. cloacae, P. mirabilis, M. morganii, P. vulgaris and P. aeruginosa) NY-198 was less active than CPFX and NFLX, and nearly as active as OFLX. Thirty-four patients suffering from respiratory tract infection received orally 400 or 600 mg of NY-198 a day. Clinical response was excellent in 2, good in 19, fair in 4, and poor in 8; 1 was not evaluated. Dizziness was observed in two and anorexia with fatiguability in one patient. No abnormalities in laboratory findings were observed.

    本文言語English
    ページ(範囲)486-494
    ページ数9
    ジャーナルChemotherapy
    36
    DOI
    出版ステータスPublished - 1988 1 1

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    フィンガープリント 「Laboratory study of NY-198 and clinical evaluation in respiratory tract infections」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

    引用スタイル